NEUCHATEL, Switzerland--(BUSINESS WIRE)--Oct. 6, 2016--
Masimo (NASDAQ:
MASI) announced today the CE marking of the Rad-97™ Pulse
CO-Oximeter®. Rad-97 offers the same Measure-through Motion
and Low Perfusion™ SET® pulse oximetry and upgradeable
rainbow SET™ technology as the Radical-7® Pulse CO-Oximeter –
in a versatile standalone monitor configuration.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20161006005510/en/
Masimo Rad-97 Pulse CO-Oximeter, featuring automatic display rotation (Photo: Business Wire)
Rad-97 features a high-resolution 1080p HD color display with
user-friendly multi-touch navigation, similar to Root® and
Radical-7, allowing clinicians to easily customize the device to best
suit their monitoring needs. Users can also rapidly configure the device
to accommodate different patient populations using customizable
profiles. Rad-97 provides both built-in wireless connectivity, via Wi-Fi
and Bluetooth®, and built-in wired options, including
Ethernet, USB, and Nurse Call Interface connections. A rechargeable
battery lasting seven hours allows Rad-97 to be used in situations where
portability or extended operation without access to power are needed.
In select markets outside the United States, Rad-97 will be available
with an optional camera, which will be used in conjunction with Masimo
Patient SafetyNet™*. The camera includes a high resolution, high-frame
rate video feed, as well as audio, to the Patient SafetyNet
view-station. The system will be able to use the hospital’s existing IT
network and to provide additional viewing of images in the same care
area. Through Rad-97, it will be possible to connect other devices a
patient may be using, such as glucometers and scales, to Patient
SafetyNet and to remotely allow for interaction between clinicians and
patients or other clinicians.
Like Radical-7, Rad-97 features Measure-through Motion and Low Perfusion
pulse oximetry (SpO2), pulse rate (PR), and perfusion index
(PI). Clinicians can add other monitoring solutions such as the rainbow
SET measurements total hemoglobin (SpHb®), methemoglobin
(SpMet®), acoustic respiration rate (RRa®),
carboxyhemoglobin (SpCO®), and oxygen content (SpOC™). In
select markets outside the United States, additional parameters such as
Oxygen Reserve Index™ (ORi™) and respiration rate from the pleth (RRp™)
are available, making Rad-97 the smallest Masimo bedside device
currently capable of monitoring the full rainbow SET platform.
“Rad-97 brings our core SET® and rainbow®
technologies to a compact new design, which will allow broader
applications in many new settings, including low-resource countries and
homes,” said Joe Kiani, Founder and CEO of Masimo. “We’ve engineered
Rad-97 to take advantage of the latest advances in adaptability and
connectivity, packaging Masimo’s industry-leading noninvasive technology
in a cost-effective monitor that will make it more accessible and useful
to clinicians and patients than ever.”
ORi and RRp parameters and the camera feature do not have 510(k)
clearance and are not available in the U.S.
@MasimoInnovates
| #Masimo
*The use of the trademark SafetyNet is under license from University
HealthSystem Consortium.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® is estimated
to be used on more than 100 million patients in leading hospitals and
other healthcare settings around the world. In 2005, Masimo introduced
rainbow® Pulse CO-Oximetry technology, allowing noninvasive and
continuous monitoring of blood constituents that previously could only
be measured invasively, including total hemoglobin (SpHb®),
oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®)
and Oxygen Reserve Index (ORi™), in addition to SpO2, pulse
rate, and perfusion index (PI). In 2014, Masimo introduced Root®,
an intuitive patient monitoring and connectivity platform with the
Masimo Open Connect (MOC-9) interface. Masimo is also taking an active
leadership role in mHealth with products such as the Radius-7™ wearable
patient monitor and the MightySat™ fingertip pulse oximeter. Additional
information about Masimo and its products may be found at www.masimo.com.
All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo’s Rad-97™ Pulse CO-Oximeter®. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that Masimo's unique noninvasive
measurement technologies, including Masimo Rad-97 Pulse CO-Oximeter,
contribute to positive clinical outcomes and patient safety; risks
related to our belief that Masimo noninvasive medical breakthroughs
provide cost-effective solutions and unique advantages; as well as other
factors discussed in the "Risk Factors" section of our most recent
reports filed with the Securities and Exchange Commission ("SEC"), which
may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161006005510/en/
Source: Masimo
Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com